
STAAR Surgical (STAA) Stock Forecast & Price Target
STAAR Surgical (STAA) Analyst Ratings
Bulls say
Staar Surgical is well-positioned for continued growth, with strong first quarter results, an increased price target, and potential for future growth in both China and the US. The company's dominant market position and proprietary Collamer material make it a potential leader in the industry. With a positive tone from management and expected increases in cash and investments, Staar Surgical is a strong investment opportunity.
Bears say
Staar Surgical is seeing strong performance in the US market driven by increased surgeon adoption and a focused marketing strategy, leading to share gains in a declining refractive surgery market. The recent FDA approval for expanded indications and underappreciated long-term growth potential make the US market a key driver for the company. The positive China revenue rebound, outperforming expectations and approaching normalized levels, is demand-driven and reflects the strong launch of EVO+ ICL. With management expecting to fully meet demand for EVO+ by end of 2Q'26, we see potential for solid full-year growth in ex-China revenue, driven by strong demand for EVO+ and management's confidence in the +MSD% to +10% range.
This aggregate rating is based on analysts' research of STAAR Surgical and is not a guaranteed prediction by Public.com or investment advice.
STAAR Surgical (STAA) Analyst Forecast & Price Prediction
Start investing in STAAR Surgical (STAA)
Order type
Buy in
Order amount
Est. shares
0 shares